EVOLVING CERVICAL CANCER SCREENING GUIDELINES AND HPV VACCINATION STATUS. A LITERATURE REVIEW
Authors:
- Zuzanna TomaszewskaZTZuzanna Tomaszewska
- Adrianna PerzanowskaAPAdrianna Perzanowska
- Anna ZielińskaAZAnna Zielińska
- Agata NowackaANAgata Nowacka
- Julia CiechanowiczJCJulia Ciechanowicz
- Stanisław CiechanowiczSCStanisław Ciechanowicz
- Julia DuraJDJulia Dura
- Marika GutowskaMGMarika Gutowska
- Piotr KupidłowskiPKPiotr Kupidłowski
- Aleksandra PrzybylskaAPAleksandra Przybylska
Open Access
- 27 August 2025
- journal article
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 2 (3(47))
Abstract
Background: Persistent infection with high-risk types of human papillomavirus is the primary cause of cervical cancer globally. Recent decades have witnessed significant advances in prevention, with the introduction of effective prophylactic HPV vaccines and highly sensitive molecular screening methods transforming how cervical cancer is detected and managed. Aim of this review is to explore the impact of HPV vaccination programs on cervical cancer prevention strategies, focusing on how vaccination coverage influences the global shift from traditional cytology-based screening to HPV DNA testing in selected high-income countries. Methodology: A comprehensive search was conducted across scientific databases, including PubMed, the Cochrane Library, and WHO reports, focusing on recent peer-reviewed studies. Results: The diagnostic performance of cytology has declined in vaccinated populations due to fewer abnormal findings, prompting a shift toward primary HPV DNA testing. This method offers sensitivity rates exceeding 90% and supports longer screening intervals of five years or more. Countries like Australia, the Netherlands, Sweden, and the UK have adopted nationwide HPV-based screening, while Poland initiated pilot HPV testing programs in 2024. However, several barriers persist, including disparities in vaccine distribution, the high cost of molecular diagnostics, and persistent public hesitancy toward vaccination. Conclusions: Combining widespread HPV vaccination with HPV DNA-based screening offers the most promising strategy for reducing cervical cancer incidence and achieving the WHO's 2030 elimination targets. Those recommendations include expanding gender-neutral vaccination, supporting transitions to HPV testing in lagging regions, and incorporating innovations like self-sampling to improve outreach and screening participation.Keywords
This publication has 30 references indexed in Scilit:
- Prophylactic HPV vaccination in HPV‐related gynecologic cancers: European Society of Gynecological Oncology (ESGO) prevention committee opinionInternational Journal of Gynecology & Obstetrics, 2024
- Participation and relative cost of attendance by direct‐mail compared to opt‐in invitation strategy for HPV self‐sampling targeting cervical screening non‐attenders: A large‐scale, randomized, pragmatic studyInternational Journal of Cancer, 2024
- Human papillomavirus (HPV) self-sampling to encourage the uptake of cervical screeningCochrane Database of Systematic Reviews, 2023
- Performance of cervical cytology and HPV testing for primary cervical cancer screening in Latin America: an analysis within the ESTAMPA studyThe Lancet Regional Health - Americas, 2023
- Widening the offer of human papillomavirus self‐sampling to all women eligible for cervical screening: Make haste slowlyInternational Journal of Cancer, 2022
- Screening for Cervical Cancer With High-Risk Human Papillomavirus TestingJAMA, 2018
- Epidemiology and burden of HPV-related diseaseBest Practice & Research Clinical Obstetrics & Gynaecology, 2018
- Safety of Human Papillomavirus Vaccines: An Updated ReviewDrug Safety, 2017
- How will transitioning from cytology toHPVtesting change the balance between the benefits and harms of cervical cancer screening? Estimates of the impact on cervical cancer, treatment rates and adverse obstetric outcomes inAustralia, a high vaccination coverage countryInternational Journal of Cancer, 2017
- Comparison of DRY and WET vaginal swabs with cervical specimens in Roche Cobas 4800 HPV and Abbott RealTime High Risk HPV testsJournal of Clinical Virology, 2016